CLONAZEPAM XGX PHARMA

Posology Dosage in epilepsy The dosage is individual and is adapted to the patient's age, clinical effect and tolerance. For further information on intravenous administration, see section

4) Not known Paradoxical reactions, including irritability, thrombophlebitis/thrombosis Injury, poisoning and procedural complications Not known Risk of falls and fracture Investigations Rare Thrombocytopenia Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store

4. 0 ml water for injections. For adults and adolescents, this dose can be repeated as needed. The maximum recommended dose in adults and adolescents is 20 mg daily. 6). 2). 4). 3). Renal impairment The safety and efficacy of clonazepam in patients with renal impairment have not been studied.

2) no dose adjustment is required in these patients. 3). Patients with mild to moderate hepatic impairment should be given the lowest possible dose. Withdrawal Clonazepam should not be discontinued abruptly. Discontinuation should be done by slow dose reduction to avoid provoking tonic clonic seizures.

Withdrawal symptoms are highly variable and can range from a few hours up to a week or more. In less severe cases withdrawal symptoms may be limited to tremor, restlessness, insomnia, anxiety, headache, and difficulty concentrating.

However, withdrawal symptoms such as sweating, muscle and abdominal spasms and altered consciousness may occur. In rare cases delirium and convulsions may occur. In the event of withdrawal symptoms careful medical monitoring and patient support are necessary.

Method of administration The product can be administered by slow intravenous injection, intravenous infusion or as an intramuscular injection. Slow intravenous injection Slow intravenous injection shoud be used for acute treatment, not for long term treatment.

0 ml water for injections to prevent local irritation at the injection site. The solution for injection should be prepared immediately before administration. Intravenous infusion The solution for infusion should be used for long term treatment and prepared immediately before administration.

All intravenous treatment should be administered slowly, with constant monitoring of EEG, respiration and blood pressure. Intramuscular injection Only in exceptional cases, where intravenous administration is not possible, intramuscular (IM) route of administration should be used, due to the slow absorption rate following IM administration.

1 or to other medicines of the benzodiazepine group. • Severe respiratory failure. • Severe hepatic impairment. • Patients who are in coma. • Patients known to be abusing pharmaceuticals, drugs or alcohol. • Children under 12 years of age.